Does LORLATINIB Cause Hyperlipidaemia? 134 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 134 reports of Hyperlipidaemia have been filed in association with LORLATINIB (Lorbrena). This represents 2.4% of all adverse event reports for LORLATINIB.
134
Reports of Hyperlipidaemia with LORLATINIB
2.4%
of all LORLATINIB reports
15
Deaths
16
Hospitalizations
How Dangerous Is Hyperlipidaemia From LORLATINIB?
Of the 134 reports, 15 (11.2%) resulted in death, 16 (11.9%) required hospitalization, and 1 (0.7%) were considered life-threatening.
Is Hyperlipidaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LORLATINIB. However, 134 reports have been filed with the FAERS database.
What Other Side Effects Does LORLATINIB Cause?
Death (1,050)
Neoplasm progression (633)
Off label use (394)
Weight increased (306)
Hallucination (290)
Blood cholesterol increased (281)
Dyspnoea (223)
Oedema peripheral (198)
Oedema (195)
Fatigue (188)
What Other Drugs Cause Hyperlipidaemia?
ALENDRONATE (511)
AMLODIPINE (226)
DENOSUMAB (204)
SITAGLIPTIN (186)
METHOTREXATE (184)
ROSUVASTATIN (179)
PREDNISONE (169)
FINASTERIDE (145)
MYCOPHENOLATE MOFETIL (141)
ASPIRIN (138)
Which LORLATINIB Alternatives Have Lower Hyperlipidaemia Risk?
LORLATINIB vs LORMETAZEPAM
LORLATINIB vs LORNOXICAM
LORLATINIB vs LOSARTAN
LORLATINIB vs LOSARTAN\LOSARTAN
LORLATINIB vs LOTEPREDNOL ETABONATE